Cited by 282Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies

Open access
Irwin, David J., Cohen, Todd J., Grossman, Murray, Arnold, Steven E., Xie, Sharon X., Lee, Virginia M.-Y., Trojanowski, John Q.·2012·Brain

Abstract

The microtubule-binding protein, tau, is the major component of neurofibrillary inclusions characteristic of Alzheimer's disease and related neurodegenerative tauopathies. When tau fibrillizes, it undergoes abnormal post-translational modifications resulting in decreased solubility and altered microtubule-stabilizing properties. Recently, we reported that the abnormal acetylation of tau at lysine residue 280 is a novel, pathological post-translational modification. Here, we performed detailed immunohistochemistry to further examine acetylated-tau expression in Alzheimer's disease and other major tauopathies. Immunohistochemistry using a polyclonal antibody specific for acetylated-tau at lysine 280 was conducted on 30 post-mortem central nervous system regions from patients with Alzheimer's disease (10 patients), corticobasal degeneration (5 patients), and progressive supranuclear palsy (5 patients). Acetylated-tau pathology was compared with the sequential emergence of other tau modifications in the Alzheimer's disease hippocampus using monoclonal antibodies to multiple well-characterized tau epitopes. All cases studied showed significant acetylated-tau pathology in a distribution pattern similar to hyperphosphorylated-tau. Acetylated-tau pathology was largely in intracellular, thioflavin-S-positive tau inclusions in Alzheimer's disease, and also thioflavin-S-negative pathology in corticobasal degeneration and progressive supranuclear palsy. Acetylated-tau was present throughout all stages of Alzheimer's disease pathology, but was more prominently associated with pathological tau epitopes in moderate to severe-stage cases. These temporal and morphological immunohistochemical features suggest acetylation of tau at this epitope is preceded by early modifications, including phosphorylation, and followed by later truncation events and cell death in Alzheimer's disease. Acetylation of tau at lysine 280 is a pathological modification that may contribute to tau-mediated neurodegeneration by both augmenting losses of normal tau properties (reduced solubility and microtubule assembly) as well as toxic gains of function (increased tau fibrillization). Thus, inhibiting tau acetylation could be a disease-modifying target for drug discovery target in tauopathies.

Integrity signals

Registry

Crossref · 10.1093/brain/aws013

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Tau acetylation at Lys280 can only be detected in AD and 4R tauopathies such as corticobasal degeneration and PSP.

    “Acetylation of tau at Lys174, Lys274, Lys280, and Lys281 have been well characterized due to their association with AD: tau acetylation at Lys280 can only be detected in AD and 4R tauopathies such as corticobasal degeneration and PSP.”
  • Increased levels of acetylated tau at Lys174, Lys274, and Lys281 have been observed in the brain of AD patients at varying disease stages.

    “Additionally, increased levels of acetylated tau at Lys174, Lys 274, and Lys281 have been observed in the brain of AD patients at varying disease stages [156–159].”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Irwin, D. J., Cohen, T. J., Grossman, M., Arnold, S. E., Xie, S. X., Lee, V. M.-Y., & Trojanowski, J. Q.
Affiliations
University of Pennsylvania (US)
Venue
Brain
Published
2012-02-24
Volume
135
Issue
3
Pages
807-818
ISSN
  • 0006-8950 (ISSN-L)
  • 1460-2156
OpenAlex
W2149168676
Cited by
281
References
49
Citations by year
2026: 15 · 2025: 17 · 2024: 13 · 2023: 23 · 2022: 24 · 2021: 26 · 2020: 24 · 2019: 14 · 2018: 19 · 2017: 23 · 2016: 17 · 2015: 16 · 2014: 22 · 2013: 21 · 2012: 7
FWCI
14.15
Type
journal article
Language
en
Open access
Locations
  • Brain (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute on Aging (P30AG010124, T32AG000255)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
tau acetylation, Alzheimer's disease, tauopathy, corticobasal degeneration, progressive supranuclear palsy, neurofibrillary tangles, tau phosphorylation, tau fibrillization, tau truncation, thioflavin S, microtubule-binding protein
MeSH terms
Acetylation, Aged, Alzheimer Disease, Epitopes, Basal Ganglia, Cerebral Cortex, Female, Humans, Immunohistochemistry, Male, Middle Aged, Nerve Degeneration, Phosphorylation, Supranuclear Palsy, Progressive, Tissue Banks, Neurofibrillary Tangles, tau Proteins, Disease Progression, Tauopathies, Proteostasis Deficiencies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review